Accueil / Communiqués / Biogennix Names Michael Roux General Manager

Biogennix Names Michael Roux General Manager

Tuesday, January 8th 2019 at 5:15pm UTC

Company Also Expands Sales, Marketing and R&D Teams

IRVINE, Calif.–(BUSINESS WIRE)– Biogennix,
an osteobiologics company that develops, manufactures, and distributes
proprietary bone graft substitutes used for bone fusion procedures, has
named Michael Roux its new General Manager.

With nearly three decades of successful technology and medical device
industry experience, Roux most recently led Product Management at
Glidewell Laboratories, a leading dental products technology
company. Previously, he served as Vice President of Product Management
with Patient Safety Technologies, acquired by Stryker in 2014. Roux also
spent time as a Global Director at Hill-Rom, as well as 3M, where he
held positions of increasing responsibility within product engineering,
six-sigma, global product marketing, and business development.

Roux holds a B.S. in Industrial Engineering from the University of
Minnesota, and an MBA in Marketing from the University of St. Thomas.

“Michael brings significant business, medical device and marketing
leadership experience to our team, positioning Biogennix for the next
level of growth,” said Clay Shors, Biogennix’s President. “He has a
strong background in product management and marketing with a wide range
of medical device and multi-national business expertise with leading
publicly-owned and privately held companies. We look forward to reaping
the benefits of his ability to consistently deliver bottom line results
in entrepreneurial to large scale global businesses through strategic
thinking, data driven decision making, innovative problem solving,
effective team building and leadership.”

In full growth mode, Biogennix has also expanded its sales, marketing
and R&D teams with some key additions: Jennifer Sorenson, Valerie
Powers, and Savvas Papanicolaou.

Earlier last month, Jennifer Sorenson was named Regional Vice President
of Sales for Biogennix. Sorenson, based out of the Dallas-Fort Worth
region, brings close to two decades of sales leadership experience, with
an extensive background in the spine, biologics and orthopedics markets.
Valerie Powers, Biogennix’s new Marketing Manager, brings a unique blend
of clinical and marketing expertise from over a decade of hospital and
medical device experience, including stints at UCLA Health, St. Joseph’s
Health, Edwards Lifesciences, and various medical start-ups. Also,
Savvas Papanicolaou, Biogennix’s new Senior Project Engineer, brings
over a decade of successful lead engineering and product design and
development experience from UC Davis Health, as well as other leading
orthopedic manufacturers.

Shors noted that with the addition of Roux, the other new team members
and several expanded sales and marketing initiatives for 2019, Biogennix
expects to continue to grow exponentially and expand upon 2018’s success.

The majority of Biogennix’s year over year growth to date is attributed
to steady increases in sales of the company’s novel bone graft
substitutes, Morpheus™ and osteoSPAN™, both of which are resorbable,
osteoconductive scaffolds ideally suited for bone regeneration. The
Morpheus product is a moldable version of osteoSPAN, which combines the
granules with an organic binder, providing optimal handling
characteristics for surgeons.

Biogennix is a leading developer of osteobiologic products specifically
designed for spine fusion and bone trauma. The company is led by a team
of scientists and industry veterans committed to delivering unique
products for bone regeneration. Biogennix designs, manufactures and
distributes all of its products from its Irvine-based facilities.

Biogennix is a fully-integrated osteobiologic company
headquartered in Irvine which develops, manufactures, and distributes
proprietary bone graft substitutes used in bone fusion procedures. Learn
more at
biogennix.com.

Contacts

Media Contact: Paul Williams, 310-569-0023, paul@medialinecommunications.com

Source: Biogennix


Voir aussi

Study Demonstrates Cook Biotech’s OASIS® Wound Matrix Has Higher Rates of Healing in Pressure Ulcers Than Standard of Care

Wednesday, February 20th 2019 at 6:30pm UTC BLOOMINGTON, Ind.–(BUSINESS WIRE)– A recently published multi-center, randomized, …